| scholarly article | Q13442814 |
| P50 | author | Joshua T. Cohen | Q37841014 |
| Gunjan L Shah | Q49391675 | ||
| Aaron N Winn | Q87849870 | ||
| P2093 | author name string | Andreas Klein | |
| Raymond Comenzo | |||
| Susan K Parsons | |||
| Pei-Jung Lin | |||
| Kenneth B Miller | |||
| Hedy P Smith | |||
| Kellie A Sprague | |||
| Rachel Buchsbaum | |||
| P2860 | cites work | Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group | Q28207984 |
| Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma | Q30409713 | ||
| Development of a comorbidity index using physician claims data | Q30623996 | ||
| Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population | Q30714715 | ||
| Comparison of SEER Treatment Data With Medicare Claims | Q30779910 | ||
| Treatments for newly diagnosed multiple myeloma: analysis of survival data and cost-effectiveness evaluation | Q32000780 | ||
| Estimating health care costs related to cancer treatment from SEER-Medicare data | Q33184145 | ||
| Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data. | Q33718192 | ||
| Therapeutic options in the treatment of multiple myeloma: pharmacoeconomic and quality-of-life considerations | Q33809965 | ||
| Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data | Q34038959 | ||
| High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma | Q34195428 | ||
| Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data | Q34539519 | ||
| Long term evaluation of the impact of autologous peripheral blood stem cell transplantation in multiple myeloma: a cost-effectiveness analysis | Q35009935 | ||
| The real world effectiveness of hematopoietic transplant among elderly individuals with multiple myeloma | Q36009600 | ||
| Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: a study using a large national private claims database | Q36312911 | ||
| Improved survival in multiple myeloma and the impact of novel therapies | Q36478461 | ||
| An update: health economics of managing multiple myeloma | Q36510055 | ||
| The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide mai | Q36565628 | ||
| Multiple myeloma treatment transformed: a population-based study of changes in initial management approaches in the United States | Q36868632 | ||
| Economic and clinical impact of multiple myeloma to managed care | Q37262116 | ||
| Critical review of economic evaluations in multiple myeloma: an overview of the economic evidence and quality of the methodology | Q37874366 | ||
| Do value thresholds for oncology drugs differ from nononcology drugs? | Q38263415 | ||
| Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold | Q39268069 | ||
| Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network | Q39332369 | ||
| Autologous transplantation and maintenance therapy in multiple myeloma | Q41756278 | ||
| Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma | Q43650924 | ||
| Cost-effectiveness of a Transplantation Strategy Compared to Melphalan and Prednisone in Younger Patients with Multiple Myeloma | Q44400609 | ||
| Single versus double autologous stem-cell transplantation for multiple myeloma. | Q44706045 | ||
| Safety and cost-effectiveness of outpatient autologous stem cell transplantation in patients with multiple myeloma | Q45836179 | ||
| Potential for cancer related health services research using a linked Medicare-tumor registry database. | Q50125205 | ||
| Cost-effectiveness analysis of early vs. late autologous stem cell transplantation in multiple myeloma. | Q51067504 | ||
| Economics of hematopoietic cell transplantation. | Q51588444 | ||
| A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome | Q71123629 | ||
| Feasibility and cost-effectiveness of outpatient autotransplants in multiple myeloma | Q73740223 | ||
| Costs of intensive treatment and follow-up of patients with multiple myeloma | Q77800151 | ||
| A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma; a prospective randomised | Q79997901 | ||
| Transplantation remains significantly underused | Q95487550 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | database | Q8513 |
| multiple myeloma | Q467635 | ||
| stem cell transplantation | Q65592366 | ||
| P304 | page(s) | 1823-1829 | |
| P577 | publication date | 2015-05-30 | |
| P1433 | published in | Biology of Blood and Marrow Transplantation | Q15754328 |
| P1476 | title | Cost-Effectiveness of Autologous Hematopoietic Stem Cell Transplantation for Elderly Patients with Multiple Myeloma using the Surveillance, Epidemiology, and End Results-Medicare Database | |
| P478 | volume | 21 |
| Q99612827 | Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma |
| Q64903997 | Association Between Autologous Stem Cell Transplant and Survival Among Californians With Multiple Myeloma. |
| Q88030952 | Evaluation of the Relevance of Surgery in Patients with Multiple Myeloma Harboring Symptomatic Spinal Involvement: A Retrospective Case Series |
| Q31095966 | Exploring Big Data in Hematological Malignancies: Challenges and Opportunities |
| Q88649770 | Hematopoietic stem cell transplantation in geriatric patients in Turkey |
| Q36473988 | Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis |
| Q89187646 | Modified High-Dose Melphalan and Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis |
| Q53123065 | Real-world economic burden of hematopoietic cell transplantation among a large US commercially insured population with hematologic malignancies. |
| Q90245548 | Special considerations for the treatment of multiple myeloma according to advanced age, comorbidities, frailty and organ dysfunction |
| Q92691459 | The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma |
| Q91692405 | Utilization of novel systemic therapies for multiple myeloma: A retrospective study of front-line regimens using the SEER-Medicare data |
| Q39103567 | VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma |
| Q52730156 | Value-Based Care in Hematopoietic Cell Transplantation and Cellular Therapy: Challenges and Opportunities. |
Search more.